JTC-801 is primarily investigated for its potential analgesic and anti-inflammatory effects, particularly in the context of pain management. It acts as a selective antagonist of the sigma-1 receptor, which plays a role in modulating pain signaling pathways, especially in neuropathic and inflammatory pain conditions. Due to this mechanism, JTC-801 has shown promise in preclinical studies for reducing chronic pain without the side effects commonly associated with opioids. It is also being explored for use in cough suppression and certain neurodegenerative conditions, owing to its central nervous system activity. Research remains largely in the experimental stage, with ongoing evaluation of its efficacy and safety profile.